Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-19 Following ASCT for High-risk Multiple Myeloma
NCT02794246Phase 2Terminated
- Sponsor
- University of Pennsylvania
- Start
- Jun 2016
- Primary completion
- Feb 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-CD19 CAR-T cells in multiple myeloma (MM), sponsored by University of Pennsylvania. Started Jun 2016; status: terminated.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02794246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794246.